Table 3.
Question | Cancer model | Biomaterials | Refs. |
---|---|---|---|
| |||
How does bone tissue recruit metastatic cancer cells? | Breast cancer | Fibrin | [87,102] |
Prostate Cancer | PCL | [91] | |
How does the bone matrix modulate cancer phenotype? | Breast cancer | Chitosan + Hydroxyapatite | [44] |
Poly-ether-urethane | [90] | ||
PLG + Hydroxyapatite | [42,43] | ||
PEGDA + Hydroxyapatite | [94] | ||
Gelatin + Hydroxyapatite | [88] | ||
Prostate cancer | PCL | [91] | |
Collagen + Hydroxyapatite | [95,121] | ||
PCL-TCP + PEGDA | [92] | ||
Hyaluronan | [89] | ||
Decellularized bone | [97] | ||
PCL/gelatin | [93] | ||
Silk | [119] | ||
How do cancer cells destroy bone tissue? | Breast Cancer | PLG + Hydroxyapatite | [42,43] |
Gelatin + Hydroxyapatite | [88] | ||
Prostate Cancer | PCL | [91] | |
Decellularized bone | [97] | ||
Silk | [119] |
PCL: poly(ε-caprolactone); PLG: poly(lactide-co-glycolide); PEGDA: poly(ethylene glycol) diacrylate; TCP: Tricalcium phosphate.